JAMA Network
About The Study: Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing epidermal growth factor receptor and anaplastic lymphoma kinase alterations when given after planned adjuvant chemotherapy and/or radiotherapy.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
